Name | Number of supported studies | Average coverage | |
---|---|---|---|
macrophage | 28 studies | 50% ± 25% | |
classical monocyte | 28 studies | 69% ± 18% | |
non-classical monocyte | 25 studies | 87% ± 14% | |
monocyte | 22 studies | 61% ± 19% | |
conventional dendritic cell | 22 studies | 38% ± 16% | |
dendritic cell | 15 studies | 36% ± 17% | |
neutrophil | 13 studies | 55% ± 14% | |
goblet cell | 10 studies | 56% ± 15% | |
type II pneumocyte | 8 studies | 68% ± 16% | |
enterocyte | 8 studies | 50% ± 25% | |
epithelial cell | 8 studies | 42% ± 19% | |
myeloid cell | 8 studies | 48% ± 17% | |
endothelial cell | 7 studies | 50% ± 30% | |
hepatocyte | 7 studies | 78% ± 26% | |
alveolar macrophage | 6 studies | 73% ± 24% | |
epithelial cell of proximal tubule | 6 studies | 44% ± 16% | |
cholangiocyte | 5 studies | 76% ± 23% | |
ciliated cell | 5 studies | 32% ± 11% | |
intermediate monocyte | 5 studies | 74% ± 25% | |
type I pneumocyte | 4 studies | 25% ± 6% | |
pancreatic A cell | 4 studies | 50% ± 11% | |
endothelial cell of sinusoid | 4 studies | 59% ± 20% | |
fibroblast | 4 studies | 27% ± 5% | |
enteroendocrine cell | 4 studies | 34% ± 20% | |
microglial cell | 4 studies | 40% ± 22% | |
inflammatory macrophage | 4 studies | 68% ± 21% | |
brush cell | 4 studies | 32% ± 4% | |
mononuclear phagocyte | 3 studies | 49% ± 27% | |
hepatic stellate cell | 3 studies | 77% ± 24% | |
smooth muscle cell | 3 studies | 32% ± 14% | |
T cell | 3 studies | 56% ± 20% | |
basal cell | 3 studies | 30% ± 10% | |
club cell | 3 studies | 37% ± 12% | |
mucus secreting cell | 3 studies | 33% ± 14% | |
monocyte-derived dendritic cell | 3 studies | 31% ± 10% | |
pancreatic ductal cell | 3 studies | 67% ± 5% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
liver | 100% | 1283619.90 | 226 / 226 | 99% | 10328.34 | 401 / 406 |
kidney | 100% | 28697.49 | 89 / 89 | 78% | 821.58 | 704 / 901 |
pancreas | 84% | 8312.40 | 277 / 328 | 87% | 1091.02 | 154 / 178 |
lung | 100% | 31240.99 | 577 / 578 | 56% | 401.43 | 647 / 1155 |
stomach | 63% | 14810.42 | 227 / 359 | 48% | 305.67 | 138 / 286 |
thymus | 41% | 1097.54 | 268 / 653 | 68% | 1046.03 | 409 / 605 |
spleen | 100% | 21384.27 | 240 / 241 | 0% | 0 | 0 / 0 |
intestine | 46% | 10109.49 | 445 / 966 | 50% | 342.89 | 262 / 527 |
peripheral blood | 82% | 109578.05 | 760 / 929 | 0% | 0 | 0 / 0 |
breast | 39% | 2557.85 | 178 / 459 | 21% | 155.33 | 232 / 1118 |
lymph node | 0% | 0 | 0 / 0 | 41% | 97.89 | 12 / 29 |
esophagus | 5% | 184.49 | 74 / 1445 | 29% | 212.20 | 53 / 183 |
bladder | 10% | 854.57 | 2 / 21 | 20% | 115.25 | 101 / 504 |
uterus | 9% | 401.42 | 15 / 170 | 12% | 58.98 | 55 / 459 |
adipose | 21% | 925.64 | 249 / 1204 | 0% | 0 | 0 / 0 |
blood vessel | 17% | 573.40 | 224 / 1335 | 0% | 0 | 0 / 0 |
ovary | 2% | 61.36 | 3 / 180 | 10% | 28.41 | 44 / 430 |
prostate | 11% | 386.35 | 28 / 245 | 0% | 0.50 | 1 / 502 |
brain | 8% | 254.73 | 210 / 2642 | 3% | 6.05 | 21 / 705 |
skin | 3% | 119.22 | 61 / 1809 | 5% | 15.01 | 22 / 472 |
adrenal gland | 4% | 105.61 | 11 / 258 | 1% | 7.69 | 3 / 230 |
tonsil | 0% | 0 | 0 / 0 | 4% | 6.37 | 2 / 45 |
heart | 4% | 145.87 | 37 / 861 | 0% | 0 | 0 / 0 |
muscle | 0% | 5.96 | 2 / 803 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 80 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0006953 | Biological process | acute-phase response |
GO_0010951 | Biological process | negative regulation of endopeptidase activity |
GO_0007596 | Biological process | blood coagulation |
GO_0005615 | Cellular component | extracellular space |
GO_0005576 | Cellular component | extracellular region |
GO_0070062 | Cellular component | extracellular exosome |
GO_0005794 | Cellular component | Golgi apparatus |
GO_0062023 | Cellular component | collagen-containing extracellular matrix |
GO_0033116 | Cellular component | endoplasmic reticulum-Golgi intermediate compartment membrane |
GO_0005788 | Cellular component | endoplasmic reticulum lumen |
GO_1904813 | Cellular component | ficolin-1-rich granule lumen |
GO_0005783 | Cellular component | endoplasmic reticulum |
GO_0031093 | Cellular component | platelet alpha granule lumen |
GO_0030134 | Cellular component | COPII-coated ER to Golgi transport vesicle |
GO_0043231 | Cellular component | intracellular membrane-bounded organelle |
GO_0004867 | Molecular function | serine-type endopeptidase inhibitor activity |
GO_0042802 | Molecular function | identical protein binding |
GO_0002020 | Molecular function | protease binding |
GO_0005515 | Molecular function | protein binding |
Gene name | SERPINA1 |
Protein name | Epididymis secretory sperm binding protein Li 44a (Serpin peptidase inhibitor clade A member 1 isoform 1) Alpha-1-antitrypsin (Alpha-1 protease inhibitor) (Alpha-1-antiproteinase) (Serpin A1) [Cleaved into: Short peptide from AAT (SPAAT)] Alpha-1-antitrypsin Serpin peptidase inhibitor clade A member 1 isoform 2 Serpin family A member 1 Alpha-1-antitrypsin (Serpin family A member 1) Alpha-1-antitrypsin (Serpin peptidase inhibitor, clade A (Alpha-1 antiproteinase, antitrypsin), member 1, isoform CRA_a) Alpha-1-antitrypsin short transcript variant 1C4 (Alpha-1-antitrypsin short transcript variant 1C5) (Serpin peptidase inhibitor clade A (Alpha-1antiproteinase, antitrypsin) member 1) |
Synonyms | hCG_2029168 PRO2209 PI PRO0684 AAT |
Description | FUNCTION: Inhibitor of serine proteases. Its primary target is elastase, but it also has a moderate affinity for plasmin and thrombin. Irreversibly inhibits trypsin, chymotrypsin and plasminogen activator. The aberrant form inhibits insulin-induced NO synthesis in platelets, decreases coagulation time and has proteolytic activity against insulin and plasmin.; FUNCTION: [Short peptide from AAT]: Reversible chymotrypsin inhibitor. It also inhibits elastase, but not trypsin. Its major physiological function is the protection of the lower respiratory tract against proteolytic destruction by human leukocyte elastase (HLE). |
Accessions | ENST00000625866.2 ENST00000636712.1 [P01009-1] ENST00000393087.9 [P01009-1] G3V544 ENST00000557492.5 ENST00000620666.3 ENST00000402629.1 [P01009-2] ENST00000627096.2 ENST00000393088.8 [P01009-1] A0A0S2Z465 A0A024R6N5 ENST00000628155.2 A0A1L7B5J3 ENST00000449399.7 [P01009-1] E9KL23 ENST00000626480.2 ENST00000448921.5 [P01009-1] P01009 ENST00000553327.5 G3V387 ENST00000631256.2 ENST00000629092.2 ENST00000404814.8 [P01009-1] ENST00000440909.5 [P01009-1] ENST00000618636.3 ENST00000627595.2 ENST00000437397.5 [P01009-1] A0A0B4J278 ENST00000627097.2 ENST00000614317.3 ENST00000556091.1 ENST00000629711.1 G3V5R8 ENST00000355814.8 [P01009-1] ENST00000489769.1 [P01009-3] G3V2B9 ENST00000625467.2 ENST00000557118.5 ENST00000554720.1 ENST00000627178.2 ENST00000556955.5 G3V4I7 A0A0G2JRN3 |